highly significantP < 0.01
Combining AZD3965 (100 mg/kg BID) and IACS-010759 (0.5 mg/kg QD) revealed a highly significant improvement in time to reach RTV4 ( P < 0.01) in both Farage and Toledo tumour models versus vehicle or either monotherapy (Fig. 5d ).